Fig. 5.

JOSD1 causes chemoresistance by stabilizing myeloid cell leukaemia 1 (MCL1). a Cell viability of ES2 and 3AO cells expressing empty vector, JOSD1 or JOSD1^C36A and treated with different doses of carboplatin (CBP). b Cell viability of ES2 and 3AO cells expressing empty vector, JOSD1 or JOSD1 and MCL1-targeting short hairpin RNAs (shRNAs) and treated with different doses of CBP. c Quantitative analysis of the apoptosis rate of ES2 cells expressing empty vector, JOSD1 or JOSD^C36A and treated with different doses of CBP. d–f In vivo growth curves and tumour weights of xenografts generated from ES2 cells expressing an empty vector, JOSD1 or JOSD1 and MCL1-targeting shRNAs and treated with CBP (50 mg/kg, three times a week). g, h H-score and representative images of immunohistochemical staining for JOSD1, MCL1 and cleaved caspase-3 in Fig. 5e. Scale bars, 250 μm. Two-tailed Student’s t test; **p < 0.01, ***p < 0.001 and ****p < 0.0001. In a and b, the data are presented as the mean ± SD, and representative results of three biological replicates are shown. In c, d, f and g, the data are presented as the mean ± SEM (n = 10)